Gene Bio Tech

086060 · KOSDAQ · ₩086060 · 진바이오텍

₩5,080▼ ₩40 (0.78%)End-of-day · Oct 27, 2026 · End-of-day prices.
Trade
Alert me

Valuation model · Discounted cash flow (DCF)

We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.

Fair value per share

₩5,295

vs the current price (₩5,080)

Enterprise value
₩36B
Equity value
₩46B
WACC
7.4%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.

Bear / Base / Bull

Bear
₩2,325
−54.2%
Base
₩5,295
+4.2%
Bull
₩10,795
+112.5%

Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.

Assumptions

Sign in to change the assumptions and see the results update. Sign in

Cycle options

Margin path

Every year uses the cycle-average margin (4.0%).

Revenue growth

  • 3.1%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (3.1% a year, annual reports), fading to 3% by year 5.

  • 3.1%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (3.1% a year, annual reports), fading to 3% by year 5.

  • 3.1%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (3.1% a year, annual reports), fading to 3% by year 5.

  • 3%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (3.1% a year, annual reports), fading to 3% by year 5.

  • 3%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (3.1% a year, annual reports), fading to 3% by year 5.

Business

  • 4%

    Operating profit as a share of revenue.

    Default: through-the-cycle average of the last 12 months and the last 5 annual reports' operating margins.

  • 27.5%

    Share of operating profit paid as corporate tax.

    Default: Korea's top corporate tax rate (25%) plus 10% local income tax.

  • 1.7%

    The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).

    Default: not in the statements, so 80% of capital spending (most spending replaces equipment that wears out).

  • 2.2%

    Money spent on factories, equipment, software and other long-term assets (% of revenue).

    Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).

  • 29%

    Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.

    Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 3 years.

Discount rate

  • 2%

    How fast cash flows keep growing every year after year 5.

    Default: about Korea's long-run inflation plus real growth.

  • 4.11%

    Yield on Korea's 10-year government bond: the return with almost no risk.

    Default: Korea Treasury Bond 10-year yield on 2026-10-28.

  • 0.6

    How much the share moves when the market moves: 1 means just like the market.

    Default: 105 weeks of weekly returns against KOSPI (official index); raw beta 0.13, adjusted toward 1 and kept between 0.6 and 2.0.

  • 5.5%

    The extra return investors want for owning shares instead of bonds.

    Default: a typical premium for Korean shares.

  • 5.61%

    The interest rate the company would pay to borrow.

    Default: the 10-year yield plus a 1.5% credit spread.

Starting point

Revenue (TTM to H1 2026)
₩89B
Net debt (borrowings and leases − cash and deposits)
−₩10B
+ Stakes and investments
₩69M
Associates, long-term financial assets and deposits (book value)
Shares
8,610,587
Share price
₩5,080
Market cap
₩44B

TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.

Past years and projection

Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.

FY2023FY2024FY2025Year 1Year 2Year 3Year 4Year 5
Revenue₩79B₩83B₩91B₩92B₩95B₩98B₩101B₩104B
Growth−4.0%4.4%9.4%3.1%3.1%3.1%3.0%3.0%
EBIT₩4B₩3.8B₩3.9B₩3.7B₩3.8B₩3.9B₩4B₩4.2B
EBIT margin5.0%4.6%4.3%4.0%4.0%4.0%4.0%4.0%
After-tax EBIT₩2.9B₩2.8B₩2.8B₩2.7B₩2.8B₩2.8B₩2.9B₩3B
+ Depreciation———₩1.6B₩1.6B₩1.7B₩1.7B₩1.8B
− Capital spending₩767M₩1.2B₩3.8B₩2B₩2.1B₩2.2B₩2.2B₩2.3B
− Working capital−₩12B₩5.3B−₩3.1B₩803M₩828M₩853M₩852M₩877M
Free cash flow———₩1.4B₩1.5B₩1.5B₩1.6B₩1.6B
Discount factor———0.9310.8670.8070.7510.700
Present value———₩1.3B₩1.3B₩1.2B₩1.2B₩1.1B

Terminal value ₩42B, worth ₩29B today: 83% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.

Cross-check: what the market has paid before

For cyclical businesses, analysts check a DCF against the multiples the stock has traded at through past cycles. Price / book is the usual anchor for them: P/E looks highest at the bottom of a cycle, when earnings are smallest, and lowest at the top. The price each band would give today:

LowTypicalHigh
Price / book (book value ₩6,533 a share)Now 0.78×₩3,9160.60×₩4,9060.75×₩6,1450.94×
Price / earnings (last 12 months: ₩426 a share)Now 11.9×₩4,0699.54×₩4,87511.4×₩8,44219.8×
P/E on run-rate earnings (Q2 2026 × 4: ₩600 a share)Now 8.46×₩5,7269.54×₩6,86011.4×₩11,87919.8×

Low, typical and high are the 10th percentile, middle and 90th percentile of month-end multiples since 2021, each against the latest report out by then, per share at today's share count; loss years and P/E above 100 are left out. Run-rate earnings are one quarter × 4, not a forecast. Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.

Sensitivity

Fair value per share as two inputs change; the middle is the current case.

WACC ↓ · Terminal growth →1.0%1.5%2.0%2.5%3.0%
6.4%₩5,923₩6,090₩6,292₩6,543₩6,864
6.9%₩5,486₩5,604₩5,743₩5,910₩6,117
7.4%₩5,119₩5,201₩5,295₩5,407₩5,541
7.9%₩4,805₩4,861₩4,924₩4,997₩5,082
8.4%₩4,535₩4,572₩4,612₩4,657₩4,709

Now (TTM)

Market cap
₩44B
Enterprise value
₩34B
P/E
11.9×
P/B
0.8×
P/S
0.5×
EV/EBITDA
—
Dividend yield
1.0%

Over time (at each year end)

20252024202320222021
Price₩4,010₩3,290₩4,360₩3,990₩5,240
Market cap₩35B₩28B₩38B₩34B₩45B
P/E9.1×9.9×14.5×22.6×—
P/B0.6×0.6×0.8×0.8×1.0×
P/S0.4×0.3×0.5×0.4×0.7×
EV/EBITDA————52.9×
Dividend yield1.2%————

Versus similar companies

CompanyP/EP/BP/SEV/EBITDADividend yield
Gene Bio Tech11.9×0.8×0.5×—1.0%
Samsung C&T17.5×0.5×1.1×—0.9%
POSCO International10.6×1.3×0.3×—3.7%
ISC41.4×5.5×11.5×—0.6%
Youngone5.1×0.7×0.7×—3.1%
Dong SUH Companies19.0×1.6×5.1×—4.1%
Shinsegae13.7×0.4×0.3×—2.1%
Similar companies (median)15.6×1.0×0.9×—2.6%

Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.

Also known as: Gene Bio Tech / 진바이오텍 / 086060 / KRX:086060

Source: KRX statistical information